Scholarlink

Purpose of Review <p>This review investigates green chemistry included in pharmaceutical synthesis with emphasis on sustainable methodologies for the environmental soundness of these processes while upholding the efficacy and safety standards of pharmaceuticals. Particular emphasis is given here to recent advances in environmentally friendly solvents, biocatalysts, continuous flow chemistry, and minimization of waste.</p> Recent Findings <p>Many sustainable breakthroughs in manufacturing have been accomplished by the leaders in the industry. The biocatalytic resolution processes at Pfizer saw a reduction in solvent consumption by 90% while the quality of the product remained. Through innovations, late-stage functionalization methods in AstraZeneca also simplify synthetic pathways to achieve a 30% waste reduction. Scalability of the continuous-flow systems has been demonstrated, with Pfizer announcing a 56% increase in productivity, while energy savings were reported at 20%. Renewable feedstock utilization, with mention given to bio-derived 2-MeTHF from corn husks, lessened carbon emissions by 10% at Pfizer. Energy costs of AstraZeneca’s photocatalytic methods were saved by 40% utilizing visible-light-driven reactions.</p> Summary <p>Despite the great progress already made, there remain challenges to be solved for the comprehensive adoption of green chemistry. Among the technical hurdles are enzyme instability in production-scale processes, price points of renewable feedstocks, and weighing sustainability versus accelerated timelines for development. Future trends highlight the integration of artificial intelligence in predictive modeling, a broader application of renewable feedstocks, and greater collaboration across other sectors in tackling technical and economic barriers. Corporate commitments to sustainability in the pharmaceutical sector—Pfizer’s net-zero emissions by 2040 and AstraZeneca’s Target Zero initiative—are complementing regulatory developments, such as the IQ Consortium’s Green Aspiration Level and evidence of the industry’s transition from experimental applications towards standardized sustainable practices. This analysis emphasizes the urgent need for continued investments in green technology and collaborative efforts across disciplines to synchronize the causes of therapeutic innovation with global health stewardship.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Green Chemistry in Pharmaceutical Industry: Sustainable Approaches to Drug Synthesis

  • 期刊论文

  • 发表日期：

    2026年4月13日

查看全文
  • Hasanain Amer Naji,
  • Sanarya Thamer Naser,
  • Hassan Ali Mohammed Jawad,
  • Entidhar Jasim Mohammed Al-Akkam,
  • Hassan Al-Karagoly,
  • Shams Layth Nayyef ALdujaili

摘要

Purpose of Review

This review investigates green chemistry included in pharmaceutical synthesis with emphasis on sustainable methodologies for the environmental soundness of these processes while upholding the efficacy and safety standards of pharmaceuticals. Particular emphasis is given here to recent advances in environmentally friendly solvents, biocatalysts, continuous flow chemistry, and minimization of waste.

Recent Findings

Many sustainable breakthroughs in manufacturing have been accomplished by the leaders in the industry. The biocatalytic resolution processes at Pfizer saw a reduction in solvent consumption by 90% while the quality of the product remained. Through innovations, late-stage functionalization methods in AstraZeneca also simplify synthetic pathways to achieve a 30% waste reduction. Scalability of the continuous-flow systems has been demonstrated, with Pfizer announcing a 56% increase in productivity, while energy savings were reported at 20%. Renewable feedstock utilization, with mention given to bio-derived 2-MeTHF from corn husks, lessened carbon emissions by 10% at Pfizer. Energy costs of AstraZeneca’s photocatalytic methods were saved by 40% utilizing visible-light-driven reactions.

Summary

Despite the great progress already made, there remain challenges to be solved for the comprehensive adoption of green chemistry. Among the technical hurdles are enzyme instability in production-scale processes, price points of renewable feedstocks, and weighing sustainability versus accelerated timelines for development. Future trends highlight the integration of artificial intelligence in predictive modeling, a broader application of renewable feedstocks, and greater collaboration across other sectors in tackling technical and economic barriers. Corporate commitments to sustainability in the pharmaceutical sector—Pfizer’s net-zero emissions by 2040 and AstraZeneca’s Target Zero initiative—are complementing regulatory developments, such as the IQ Consortium’s Green Aspiration Level and evidence of the industry’s transition from experimental applications towards standardized sustainable practices. This analysis emphasizes the urgent need for continued investments in green technology and collaborative efforts across disciplines to synchronize the causes of therapeutic innovation with global health stewardship.